Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
Joseph J Eron,Chloe Orkin,Douglas Cunningham,Federico Pulido,Frank A Post,Stéphane De Wit,Erkki Lathouwers,Veerle Hufkens,John Jezorwski,Romana Petrovic,Kimberley Brown,Erika Van Landuyt,Magda Opsomer,EMERALD study group,S De Wit,E Florence,M Moutschen,E Van Wijngaerden,L Vandekerckhove,B Vandercam,J Brunetta,B Conway,M Klein,D Murphy,A Rachlis,S Shafran,S Walmsley,F Ajana,L Cotte,P-M Girardy,C Katlama,J-M Molina,I Poizot-Martin,F Raffi,D Rey,J Reynes,E Teicher,Y Yazdanpanah,J Gasiorowski,W Halota,A Horban,A Piekarska,A Witor,J R Arribas,I Perez-Valero,J Berenguer,J Casado,J M Gatell,F Gutierrez,M J Galindo,M D M Gutierrez,J A Iribarren,H Knobel,E Negredo,J A Pineda,D Podzamczer,J Portilla Sogorb,F Pulido,C Ricart,A Rivero,I Santos Gil,A Blaxhult,L Flamholc,M Gisslèn,A Thalme,J Fehr,A Rauch,M Stoeckle,A Clarke,B G Gazzard,M A Johnson,C Orkin,F Post,A Ustianowski,L Waters,J Bailey,P Benson,L Bhatti,I Brar,U F Bredeek,C Brinson,G Crofoot,D Cunningham,E DeJesus,C Dietz,R Dretler,J Eron,F Felizarta,C Fichtenbaum,J Gallant,J Gathe,D Hagins,S Henn,W K Henry,G Huhn,M Jain,C Lucasti,C Martorell,C McDonald,A Mills,J Morales-Ramirez,K Mounzer,R Nahass,H Olivet,O Osiyemi,D Prelutsky,M Ramgopal,B Rashbaum,G Richmond,P Ruane,A Scarsella,A Scribner,P Shalit,D Shamblaw,J Slim,K Tashima,G Voskuhl,D Ward,A Wilkin,J de Vente
DOI: https://doi.org/10.1016/j.antiviral.2019.104543
Abstract:Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. At week 52 participants in the boosted PI arm were offered switch to D/C/F/TAF (late-switch, 44 weeks D/C/F/TAF exposure). All participants were followed on D/C/F/TAF until week 96. Efficacy endpoints were percentage cumulative protocol-defined virologic rebound (PDVR; confirmed viral load [VL] ≥50 copies/mL) and VL < 50 copies/mL (virologic suppression) and ≥50 copies/mL (VF) (FDA-snapshot analysis). Of 1141 randomized patients, 1080 continued in the extension phase. Few patients had PDVR (D/C/F/TAF: 3.1%, 24/763 cumulative through week 96; late-switch: 2.3%, 8/352 week 52-96). Week 96 virologic suppression was 90.7% (692/763) (D/C/F/TAF) and 93.8% (330/352) (late-switch). VF was 1.2% and 1.7%, respectively. No darunavir, primary PI, tenofovir or emtricitabine resistance-associated mutations were observed post-baseline. No patients discontinued for efficacy-related reasons. Few discontinued due to adverse events (2% D/C/F/TAF arm). Improved renal and bone parameters were maintained in the D/C/F/TAF arm and observed in the late-switch arm, with small increases in total cholesterol/high-density-lipoprotein-cholesterol ratio. A study limitation was the lack of a control arm in the week 96 analysis. Through 96 weeks, D/C/F/TAF resulted in low PDVR rates, high virologic suppression rates, very few VFs, and no resistance development. Late-switch results were consistent with D/C/F/TAF week 48 results. EMERALD week 96 results confirm the efficacy, high genetic barrier to resistance and safety benefits of D/C/F/TAF.